Please use this identifier to cite or link to this item:
|Title:||Outcomes of non-cystic fibrosis-related bronchiectasis post-lung transplantation.||Austin Authors:||Kennedy, Jessica L;Walker, Anne;Ellender, Claire M;Steinfort, Kate;Martin, Catherine;Smith, Catherine;Snell, Gregory;Whitford, Helen||Affiliation:||Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia..
Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia..
Department of Respiratory and Sleep Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia..
Respiratory and Sleep Medicine
Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia..
School of Medicine, Dentistry and Health Science, Melbourne University, Melbourne, Victoria, Australia..
|Issue Date:||Jun-2022||Date:||2022||Publication information:||Internal medicine journal 2022; 52(6): 995-1001||Abstract:||Lung transplantation is a recognised treatment for end-stage lung disease due to bronchiectasis. Non-cystic fibrosis (CF) bronchiectasis and CF are often combined into one cohort; however, outcomes for non-CF bronchiectasis patients vary between centres, and in comparison with those for CF. To compare lung transplantation mortality and morbidity of bronchiectasis (non-CF) patients with those with CF and other indications. Retrospective analysis of patients undergoing lung transplantation between 1 January 2008 and 31 December 2013. Time to and cause of lung allograft loss was censored on 1 April 2018. A case-note review was conducted on a subgroup of 78 patients, to analyse hospital admissions as a marker of morbidity. A total of 341 patients underwent lung transplantation; 22 (6%) had bronchiectasis compared with 69 (20%) with CF. The 5-year survival for the bronchiectasis group was 32%, compared with CF (69%), obstructive lung disease (OLD) (64%), pulmonary hypertension (62%) and ILD (55%) (P = 0.008). Lung allograft loss due to chronic lung allograft dysfunction with predominant infection was significantly higher in the bronchiectasis group at 2 years. The rate of acute admissions was 2.24 higher in the bronchiectasis group when compared with OLD (P = 0.01). Patients with bronchiectasis spent 45.81 days in hospital per person year after transplantation compared with 18.21 days for CF. Bronchiectasis patients in the present study had a lower 5-year survival and poorer outcomes in comparison with other indications including CF. Bronchiectasis should be considered a separate entity to CF in survival analysis.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/30465||DOI:||10.1111/imj.15256||ORCID:||https://orcid.org/0000-0003-2086-743X||Journal:||Internal medicine journal||PubMed URL:||33656222||PubMed URL:||https://pubmed.ncbi.nlm.nih.gov/33656222/||Type:||Journal Article||Subjects:||bronchiectasis
respiratory tract disease
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 10, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.